Conditions

Subcategories:Axial Spondyloarthritis Gout and Crystalline Arthritis Guidelines Myositis Osteoarthritis and Bone Disorders Other Rheumatic Conditions Pain Syndromes Pediatric Conditions Psoriatic Arthritis Rheumatoid Arthritis Sjögren’s Disease Soft Tissue Pain Systemic Lupus Erythematosus Systemic Sclerosis Vasculitis

The ACR/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis

From the College | July 9, 2021

ATLANTA—The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover…

Researchers Explore Response to COVID-19 Vaccines in the Elderly

Ruth Jessen Hickman, MD | July 6, 2021

A delayed second dose of an mRNA vaccine may provide better protection against COVID-19 in elderly patients.

Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

Susan Bernstein | July 6, 2021

Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

New Insights into CD8+ T Cells & Lupus

Lara C. Pullen, PhD | July 6, 2021

A recent study demonstrated that exposure to type I interferon contributes to the pathogenesis of SLE via the metabolic rewiring of CD8+ T cells, which promotes cell death.

Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP | June 29, 2021

In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.

COVID-19 Puts Latino Patients with Rheumatic Disease at Risk of a Disease Flare

Arthritis & Rheumatology | June 28, 2021

In their new study, Fike et al. found Latino patients with rheumatic diseases have a higher rate of COVID-19 than the general Latino population. Obesity is a risk factor for COVID-19, and COVID-19 is a risk factor for rheumatic disease flare.

Untangling the Diagnosis & Management of GCA

Jason Liebowitz, MD, FACR | June 28, 2021

Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.

Grinding Away: An Overview of Progress in the Treatment & Management of Osteoarthritis

Jason Liebowitz, MD, FACR | June 28, 2021

Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR | June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Tofacitinib Promising for COVID-19 Pneumonia

Reuters Staff | June 22, 2021

(Reuters)—Pfizer Inc. said on June 16 its oral rheumatoid arthritis (RA) drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s main goal. Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published…